Cours Peregrine Pharmaceuticals Nasdaq
Actions
US7136613046
Produits pharmaceutiques
CA 2024 * | 139 M 126 M | CA 2025 * | 164 M 148 M | Capitalisation | 524 M 474 M |
---|---|---|---|---|---|
Résultat net 2024 * | -20 M -18,09 M | Résultat net 2025 * | -11 M -9,95 M | VE / CA 2024 * | 3,77 x |
Trésorerie nette 2024 * | - 0 | Trésorerie nette 2025 * | - 0 | VE / CA 2025 * | 3,19 x |
PER 2024 * |
-26
x | PER 2025 * |
-44
x | Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 98,9% |
Dernier transcript sur Peregrine Pharmaceuticals
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Nicholas Green
CEO | Chief Executive Officer | 60 | 30/07/20 |
Daniel Hart
DFI | Director of Finance/CFO | 50 | 01/08/18 |
Nick Ferguson
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/99 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Gregory Sargen
BRD | Director/Board Member | 59 | 27/11/17 |
Joseph Carleone
CHM | Chairman | 78 | 27/11/17 |
Catherine Mackey
BRD | Director/Board Member | 68 | 25/07/19 |
Varia. 1 janv. | Capi. | |
---|---|---|
-3,79% | 88,14 Md | |
+1,45% | 40,51 Md | |
-15,94% | 31,67 Md | |
+52,66% | 24,62 Md | |
-14,50% | 15,65 Md | |
-14,38% | 12,07 Md | |
-9,12% | 11,97 Md | |
-42,56% | 11,61 Md | |
+4,87% | 8,81 Md |